Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UKKoen B. Pouwels, Andrew Walker, Emma Pritchard et al.|Nature Medicine|2021Cited by 564
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trialSanjay Ramakrishnan, Mona Bafadhel, Dan V. Nicolau et al.|The Lancet Respiratory Medicine|2021Cited by 434
Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccineRebecca Payne, Victoria Hall, Sandra Adele et al.|Cell|2021Cited by 352
Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccinesJia Wei, Helen Fryer, Koen B. Pouwels et al.|Nature Medicine|2022Cited by 268
Anti-spike antibody response to natural SARS-CoV-2 infection in the general populationJia Wei, David Bonsall, Philippa C. Matthews et al.|Nature Communications|2021Cited by 147